Glycopeptide antibiotic

This page covers all Glycopeptide antibiotic drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Bacterial peptidoglycan (D-Ala-D-Ala), D-Ala-D-Ala peptidoglycan precursor, Bacterial cell wall (peptidoglycan precursors).

Targets

Bacterial peptidoglycan (D-Ala-D-Ala) · D-Ala-D-Ala peptidoglycan precursor · Bacterial cell wall (peptidoglycan precursors) · cell wall precursors · D-alanyl-D-alanine terminus of cell wall precursors · Bacterial peptidoglycan D-Ala-D-Ala precursors

Marketed (11)

• Intraoperative Intraosseous Vancomycin · OrthoCarolina Research Institute, Inc. · Orthopedic Surgery / Surgical Prophylaxis
  Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, delivered intraoperatively into bone to prevent surgical site infections.
• Vancomycin CI · Wake Forest University Health Sciences · Infectious Disease
  Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall rupture.
• Teicoplanin antimicrobial-lock solution · Clinica Universidad de Navarra, Universidad de Navarra · Infectious Disease
  Teicoplanin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
• Vancomycin (POC) · University of Maryland, Baltimore · Infectious Disease
  Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall rupture.
• Vancomycin with Taper/Pulse · VA Office of Research and Development · Infectious Disease
  Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, and a taper/pulse dosing regimen modulates exposure to reduce toxicity while maintaining efficacy.
• Vancomycin - model-based dosing regimen · Murdoch Childrens Research Institute · Infectious Disease
  Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.
• Vancomycin intermittent dosing interval · Massachusetts General Hospital · Infectious Disease
  Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
• Administration of Vancomycin · University of Colorado, Denver · Infectious Disease
  Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptide precursors and preventing peptidoglycan cross-linking.
• Vancomycin antimicrobial-lock solution · Clinica Universidad de Navarra, Universidad de Navarra · Infectious Disease
  Vancomycin antimicrobial-lock solution works by binding to bacterial cell wall precursors and inhibiting peptidoglycan synthesis, killing susceptible bacteria when used as a lock solution in central venous catheters.
• Vancomycin IV · Debiopharm International SA · Infectious Disease
  Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.
• Vancomycin II · Wake Forest University Health Sciences · Infectious Disease
  Vancomycin II inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.

Phase 3 pipeline (9)

• Vancomycin antibiotic powder · Major Extremity Trauma Research Consortium · Infectious Disease
  Vancomycin works by inhibiting cell wall synthesis in bacteria, ultimately leading to cell lysis and death.
• Vancomycin oral liquid · Astellas Pharma Europe B.V. · Infectious Diseases
  Vancomycin oral liquid inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
• Vancomycin inhalation powder · Savara Inc. · Infectious Disease
  Vancomycin inhalation powder works by inhibiting bacterial cell wall synthesis.
• Comparator: vancomycin · Merck Sharp & Dohme LLC · Infectious Disease
  Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
• Empirical Vancomycin · Memorial Sloan Kettering Cancer Center · Infectious Disease / Oncology (supportive care in cancer patients)
  Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
• Vancomycin (or equivalent) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Infectious Diseases
  Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
• Vancomycin capsules · Astellas Pharma Europe B.V. · Infectious Diseases
  Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
• Vancomycin 1.1% · Kurobe LLC · Infectious Disease
  Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
• Prophylactic Vancomycin · Memorial Sloan Kettering Cancer Center · Oncology / Infectious Disease Prevention
  Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.